Literature DB >> 11922186

Origins of cancer therapy.

R J Papac1.   

Abstract

This is a brief overview of the development of cancer therapy with a focus on systemic therapy. The modern era of chemotherapy developed at Yale University Medical School during World War II, a fact that has been generally unrecognized until recently. The observations preceding and involved in the discovery of effective drugs for cancer seem particularly pertinent for this anniversary year.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11922186      PMCID: PMC2588755     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  13 in total

Review 1.  Historic milestones in radiobiology and radiation therapy.

Authors:  H S Kaplan
Journal:  Semin Oncol       Date:  1979-12       Impact factor: 4.929

2.  The initial clinical trial of nitrogen mustard.

Authors:  A GILMAN
Journal:  Am J Surg       Date:  1963-05       Impact factor: 2.565

3.  The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides.

Authors:  A Gilman; F S Philips
Journal:  Science       Date:  1946-04-05       Impact factor: 47.728

4.  EXPERIMENTAL AND CLINICAL STUDIES ON THE TREATMENT OF CANCER BY DICHLORETHYLSULPHIDE (MUSTARD GAS.

Authors:  F E Adair; H J Bagg
Journal:  Ann Surg       Date:  1931-01       Impact factor: 12.969

5.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

Authors:  M S Czuczman; A J Grillo-López; C A White; M Saleh; L Gordon; A F LoBuglio; C Jonas; D Klippenstein; B Dallaire; C Varns
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 6.  The historical development of cancer chemotherapy.

Authors:  J H Burchenal
Journal:  Semin Oncol       Date:  1977-06       Impact factor: 4.929

7.  [The contraceptive pill and vascular accidents].

Authors:  M Lancet
Journal:  Harefuah       Date:  1983-02-01

8.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Authors:  Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

9.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

10.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Authors:  S L Soignet; P Maslak; Z G Wang; S Jhanwar; E Calleja; L J Dardashti; D Corso; A DeBlasio; J Gabrilove; D A Scheinberg; P P Pandolfi; R P Warrell
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

View more
  17 in total

Review 1.  Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948.

Authors:  Peter D Spain; Nina Kadan-Lottick
Journal:  J R Soc Med       Date:  2012-04       Impact factor: 5.344

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Authors:  Chiranjib Chakraborty; C George Priya Doss; Renu Sarin; Minna J Hsu; Govindasamy Agoramoorthy
Journal:  Protoplasma       Date:  2015-02-20       Impact factor: 3.356

Review 4.  Mitochondria in cancer metabolism, an organelle whose time has come?

Authors:  Rebecca G Anderson; Lais P Ghiraldeli; Timothy S Pardee
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-26       Impact factor: 10.680

5.  'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics.

Authors:  Sampath C Abeylath; Mansoor M Amiji
Journal:  Bioorg Med Chem       Date:  2011-09-17       Impact factor: 3.641

6.  Coordinated effects of microRNA-494 induce G₂/M arrest in human cholangiocarcinoma.

Authors:  Sumitaka Yamanaka; Nathaniel R Campbell; Fangmei An; Scot C Kuo; James J Potter; Esteban Mezey; Anirban Maitra; Florin M Selaru
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

Review 7.  Tuberculosis: mother of thoracic surgery then and now, past and prospectives: a review.

Authors:  Tamas F Molnar
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 8.  Recent advances of cocktail chemotherapy by combination drug delivery systems.

Authors:  Quanyin Hu; Wujin Sun; Chao Wang; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2015-11-06       Impact factor: 15.470

9.  Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.

Authors:  Sarah Crawford
Journal:  Front Pharmacol       Date:  2013-06-25       Impact factor: 5.810

Review 10.  Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review).

Authors:  Stefan Langhammer
Journal:  Oncol Rep       Date:  2013-07-22       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.